Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine

Piero Barbanti, Fiorella Guadagni, Maria Laura De Marchis, Cristiano Ialongo, Gabriella Egeo, Luisa Fofi, Cinzia Aurilia, Domenica Lovero, David Della Morte, Patrizia Ferroni, Raffaele Palmirotta

Research output: Contribution to journalArticle

Abstract

Dopamine-beta-hydroxylase (DBH) enzyme activity is modulated at the genetic level by the presence of several polymorphisms. Among these, the 19-bp insertion/deletion (I/D) polymorphism (rs72393728/rs141116007) was investigated in several genetic association studies for its correlation with the susceptibility to develop episodic migraine, but conflicting results were achieved. In the present study we analyzed this genetic variant in a carefully characterized population of migraineurs encompassing both episodic and chronic migraine (with and without medication overuse) with the aim to perform a replication study and verify any possible correlation with migraine endophenotypes. Genotyping of the DBH 19-bp I/D polymorphism was performed on 400 migraine patients and 204 healthy individuals. The associations between genotypic frequencies and the clinical and sociodemographic features of migraineurs were then investigated. The DBH 19-bp I/D polymorphism did not correlate with migraine susceptibility or most clinical variables, with the exception of a statistically significant correlation within the subgroup of patients affected by chronic migraine were the individuals carrying the deleted (D) allele were significantly more prone to abuse in analgesics. As a result of this finding, the DBH 19-bp I/D polymorphism does not influence migraine susceptibility, but it might contribute to the development of medication overuse in patient with chronic migraine.

Original languageEnglish (US)
Pages (from-to)1717-1724
Number of pages8
JournalNeurological Sciences
Volume40
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Dopamine beta-Hydroxylase
Migraine Disorders
Endophenotypes
Prescription Drug Overuse
Genetic Association Studies
Analgesics
Alleles
Enzymes

Keywords

  • 19-bp insertion/deletion polymorphism
  • Dopamine-beta-hydroxylase
  • Genetic
  • Medication overuse
  • Migraine

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Barbanti, P., Guadagni, F., De Marchis, M. L., Ialongo, C., Egeo, G., Fofi, L., ... Palmirotta, R. (2019). Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine. Neurological Sciences, 40(8), 1717-1724. https://doi.org/10.1007/s10072-019-03865-9

Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine. / Barbanti, Piero; Guadagni, Fiorella; De Marchis, Maria Laura; Ialongo, Cristiano; Egeo, Gabriella; Fofi, Luisa; Aurilia, Cinzia; Lovero, Domenica; Della Morte, David; Ferroni, Patrizia; Palmirotta, Raffaele.

In: Neurological Sciences, Vol. 40, No. 8, 01.08.2019, p. 1717-1724.

Research output: Contribution to journalArticle

Barbanti, P, Guadagni, F, De Marchis, ML, Ialongo, C, Egeo, G, Fofi, L, Aurilia, C, Lovero, D, Della Morte, D, Ferroni, P & Palmirotta, R 2019, 'Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine', Neurological Sciences, vol. 40, no. 8, pp. 1717-1724. https://doi.org/10.1007/s10072-019-03865-9
Barbanti, Piero ; Guadagni, Fiorella ; De Marchis, Maria Laura ; Ialongo, Cristiano ; Egeo, Gabriella ; Fofi, Luisa ; Aurilia, Cinzia ; Lovero, Domenica ; Della Morte, David ; Ferroni, Patrizia ; Palmirotta, Raffaele. / Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine. In: Neurological Sciences. 2019 ; Vol. 40, No. 8. pp. 1717-1724.
@article{e978b5c305d2432496382e55437a7969,
title = "Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine",
abstract = "Dopamine-beta-hydroxylase (DBH) enzyme activity is modulated at the genetic level by the presence of several polymorphisms. Among these, the 19-bp insertion/deletion (I/D) polymorphism (rs72393728/rs141116007) was investigated in several genetic association studies for its correlation with the susceptibility to develop episodic migraine, but conflicting results were achieved. In the present study we analyzed this genetic variant in a carefully characterized population of migraineurs encompassing both episodic and chronic migraine (with and without medication overuse) with the aim to perform a replication study and verify any possible correlation with migraine endophenotypes. Genotyping of the DBH 19-bp I/D polymorphism was performed on 400 migraine patients and 204 healthy individuals. The associations between genotypic frequencies and the clinical and sociodemographic features of migraineurs were then investigated. The DBH 19-bp I/D polymorphism did not correlate with migraine susceptibility or most clinical variables, with the exception of a statistically significant correlation within the subgroup of patients affected by chronic migraine were the individuals carrying the deleted (D) allele were significantly more prone to abuse in analgesics. As a result of this finding, the DBH 19-bp I/D polymorphism does not influence migraine susceptibility, but it might contribute to the development of medication overuse in patient with chronic migraine.",
keywords = "19-bp insertion/deletion polymorphism, Dopamine-beta-hydroxylase, Genetic, Medication overuse, Migraine",
author = "Piero Barbanti and Fiorella Guadagni and {De Marchis}, {Maria Laura} and Cristiano Ialongo and Gabriella Egeo and Luisa Fofi and Cinzia Aurilia and Domenica Lovero and {Della Morte}, David and Patrizia Ferroni and Raffaele Palmirotta",
year = "2019",
month = "8",
day = "1",
doi = "10.1007/s10072-019-03865-9",
language = "English (US)",
volume = "40",
pages = "1717--1724",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia",
number = "8",

}

TY - JOUR

T1 - Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine

AU - Barbanti, Piero

AU - Guadagni, Fiorella

AU - De Marchis, Maria Laura

AU - Ialongo, Cristiano

AU - Egeo, Gabriella

AU - Fofi, Luisa

AU - Aurilia, Cinzia

AU - Lovero, Domenica

AU - Della Morte, David

AU - Ferroni, Patrizia

AU - Palmirotta, Raffaele

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Dopamine-beta-hydroxylase (DBH) enzyme activity is modulated at the genetic level by the presence of several polymorphisms. Among these, the 19-bp insertion/deletion (I/D) polymorphism (rs72393728/rs141116007) was investigated in several genetic association studies for its correlation with the susceptibility to develop episodic migraine, but conflicting results were achieved. In the present study we analyzed this genetic variant in a carefully characterized population of migraineurs encompassing both episodic and chronic migraine (with and without medication overuse) with the aim to perform a replication study and verify any possible correlation with migraine endophenotypes. Genotyping of the DBH 19-bp I/D polymorphism was performed on 400 migraine patients and 204 healthy individuals. The associations between genotypic frequencies and the clinical and sociodemographic features of migraineurs were then investigated. The DBH 19-bp I/D polymorphism did not correlate with migraine susceptibility or most clinical variables, with the exception of a statistically significant correlation within the subgroup of patients affected by chronic migraine were the individuals carrying the deleted (D) allele were significantly more prone to abuse in analgesics. As a result of this finding, the DBH 19-bp I/D polymorphism does not influence migraine susceptibility, but it might contribute to the development of medication overuse in patient with chronic migraine.

AB - Dopamine-beta-hydroxylase (DBH) enzyme activity is modulated at the genetic level by the presence of several polymorphisms. Among these, the 19-bp insertion/deletion (I/D) polymorphism (rs72393728/rs141116007) was investigated in several genetic association studies for its correlation with the susceptibility to develop episodic migraine, but conflicting results were achieved. In the present study we analyzed this genetic variant in a carefully characterized population of migraineurs encompassing both episodic and chronic migraine (with and without medication overuse) with the aim to perform a replication study and verify any possible correlation with migraine endophenotypes. Genotyping of the DBH 19-bp I/D polymorphism was performed on 400 migraine patients and 204 healthy individuals. The associations between genotypic frequencies and the clinical and sociodemographic features of migraineurs were then investigated. The DBH 19-bp I/D polymorphism did not correlate with migraine susceptibility or most clinical variables, with the exception of a statistically significant correlation within the subgroup of patients affected by chronic migraine were the individuals carrying the deleted (D) allele were significantly more prone to abuse in analgesics. As a result of this finding, the DBH 19-bp I/D polymorphism does not influence migraine susceptibility, but it might contribute to the development of medication overuse in patient with chronic migraine.

KW - 19-bp insertion/deletion polymorphism

KW - Dopamine-beta-hydroxylase

KW - Genetic

KW - Medication overuse

KW - Migraine

UR - http://www.scopus.com/inward/record.url?scp=85069054687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069054687&partnerID=8YFLogxK

U2 - 10.1007/s10072-019-03865-9

DO - 10.1007/s10072-019-03865-9

M3 - Article

VL - 40

SP - 1717

EP - 1724

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 8

ER -